Clinical trials: Percutaneous Left Atrial Appendage Occlusion (LAAO)
Atrial Fibrillation, Atrial Arrhythmia
Studying Heart Ablation After Left Atrial Closure in High-Bleeding-Risk Atrial Fibrillation Patients
The purpose of this multicenter study is to collect information from routine clinical practices for patients with left atrial appendage occlusion (LAAO) devices presenting for pulmonary vein isolation (PVI) or left atrial…
- Trial name
- PROCEED-AF (NCT07580937)
- Testing
- Data collection
- Where
- 20 sites in United States, Belgium and 7 more
- Volunteers
- 198 people
- Sponsor
- University of Chicago
Atrial Fibrillation, Coronary Artery Disease
LAAO With DAPT Versus Antithrombotic Therapy
This study will retrospectively review and compare clinical outcomes between left atrial appendage occlusion with dual antiplatelet therapy versus conventional antithrombotic therapy in patients with atrial fibrillation…
- Trial name
- NCT03310801
- Testing
- ACP or Watchman
- Volunteers
- 480 people
- Sponsor
- Korea University Anam Hospital
Percutaneous Left Atrial Appendage Occlusion (LAAO), Device-related Thrombus (DRT)
Recurrent or Persistent Device Related Thrombus After Left Atrial Appendage Occlusion: The RE-DRT Study
This study is a prospective, multicenter international trial aimed at assessing the actual incidence, identifying associated factors, and evaluating the clinical consequences of both persistent and recurrent device-related…
- Conditions
- Percutaneous Left Atrial Appendage Occlusion (LAAO), Device-related Thrombus (DRT), Thromboembolic Event, Major Cardioembolic Events
- Trial name
- RE-DRT (NCT06177704)
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
Atrial Fibrillation
Surgical vs Percutaneous LAAO
Atrial fibrillation is the most common cardiac arrythmia globally. Its prevalence ranges between 2-4% worldwide. It is associated with significant morbidity and mortality.
- Trial name
- NCT05420701
- Testing
- TEE
- Volunteers
- 260 people
- Sponsor
- Chinese University of Hong Kong
Atrial Fibrillation, Percutaneous Coronary Intervention
LAAO Versus NOAC in Patients with AF and PCI
Atrial fibrillation (AF) coincides with coronary artery disease (CAD) shared common risk factors and pathophysiologic pathways. CAD affects approximately 25% of AF patient according to the trial Atrial Fibrillation Follow-up…
- Trial name
- NCT05353140
- Testing
- The WATCHMAN/WATCHMAN FLX device, Rivaroxaban + Clopidogre, Aspirin + Clopidogrel
- Where
- China
- Volunteers
- 1,386 people
- Sponsor
- Xijing Hospital